FDA approves the first 7 T MRI device for clinical use in the US

So for those currently dissatisfied with the capabilities of 1.5 T and 3 T MRI imaging technology, the US Food and Drug Administration has just approved a 7 T MRI device called a “Siemens Magnetom Terra”. … READ MORE …

More reports from the EAU “Update on Prostate Cancer”

Dr. Zachary Klaassen and UroToday have provided us with four more interesting summaries of presentations by faculty at the European Association for Urology (EAU)’s meeting in Vienna last weekend. … READ MORE …

What’s luminal water imaging, and do we need to care?

Two recent papers by Sabouri et al. have suggested that a new MRI techique known as “luminal water imaging” may be able to improve the ability of MR scans to identify and grade prostate cancer prior to biopsy. … READ MORE …

Carbon-11-labeled sarcosine as a prostate cancer imaging agent

A new paper in the Journal of Nuclear Medicine has reported the first use of [11C]sarcosine in combination with PET/CT scanning as a technique for imaging prostate cancer in man. … READ MORE …

New CureTalks program on modern forms of prostate imaging

Our next CureTalks program will be on the evolving role of imaging in the diagnosis and management of prostate cancer on Thursday, July 27, at 5:00 p.m. Pacific / 8:00 p.m. Eastern time. … READ MORE …

Enter the “director of prostate imaging” (at least at some centers)

As regular readers are well aware, there has for a while been an increase in the importance of new forms of high quality imaging studies in the diagnosis, work-up, and monitoring of men with prostate cancer (localized, locally advanced, and advanced). … READ MORE …

Axumin-enhanced PET scans becoming more widely available

Because the new imaging agent known as [18F]fluciclovine (Axumin®) is the only such imaging agent approved for use in the US — other than the [11C]choline imaging agent (use of which is limited to the Mayo Clinic) — we have been monitoring access to this new agent with some interest. … READ MORE …